ATB 1651
Alternative Names: ATB-1651Latest Information Update: 28 Mar 2024
At a glance
- Originator AmtixBio
- Class Antifungals; Skin disorder therapies
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Onychomycosis
- Preclinical Dermatomycoses
Most Recent Events
- 25 Mar 2024 AmtixBio plans a phase II trial for Onchomycosis in New Zealand (Topical) (NCT06327295)
- 20 Sep 2023 AmtixBio completed a phase I trial for Onychomycosis in New Zealand (Topical) (NCT05089409)
- 03 Feb 2022 Phase-I clinical trials in Onychomycosis in New Zealand (Topical) (NCT05089409)